BMS Extends Manufacturing Pact with Samsung Biologics

By Supplier News - DCAT Publisher

April 23, 2014

Bristol-Myers Squibb and Samsung Biologics will increase the scope of their existing manufacturing agreement in which Samsung will manufacture commercial drug substances and drug product for several Bristol-Myers Squibb biologic medicines at its Incheon, South Korea manufacturing site. Financial terms of the agreement are not disclosed.

Bristol-Myers Squibb and Samsung announced their first manufacturing agreement in July 2013 to collaborate in the production of a single commercial antibody cancer drug substance.

In addition to its current biologics manufacturing facility in Incheon, the company is currently building a second facility, also in Incheon, which is expected to be completed in early 2015.

Source: Bristol-Myers Squibb